Features associated with, and the impact of, hemolytic anemia in patients with systemic lupus erythematosus: LX, results from a multiethnic cohort

Arthritis Care and Research

Volumn 59, Issue 9, 2008, Pages 1332-1340

  Durán, Sergio ^a   Apte, Mandar ^a   Alarcón, Graciela S ^a,e   Marion, Miranda C ^b   Edberg, Jeffrey C ^a   Kimberly, Robert P ^a   Zhang, Jie ^a   Langefeld, Carl D ^b   Vilá, Luis M ^c   Reveille, John D ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^d UNIVERSITY OF TEXAS   (United States)

^e 830 Faculty Office Tower ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD16 ANTIGEN; FAS LIGAND; FC RECEPTOR IIA; FC RECEPTOR IIB;

ADULT; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DNA POLYMORPHISM; ETHNICITY; FEMALE; GENETIC CORRELATION; HEMOLYTIC ANEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; SOCIOECONOMICS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; AFRICAN AMERICAN; CAUCASIAN; ETHNIC GROUP; ETHNOLOGY; GENETICS; HISPANIC; LONGITUDINAL STUDY; MORTALITY; PATHOPHYSIOLOGY; STATISTICS; SURVIVAL RATE; UNITED STATES;

ADULT; AFRICAN AMERICANS; ANEMIA, HEMOLYTIC; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; SURVIVAL RATE; THROMBOCYTOPENIA; UNITED STATES;

EID: 54949093195     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.24020     Document Type: Article

References (45)

1. Vila LM, Alarcon GS, McGwin G Jr, Bastian HM, Fessler BJ, Reveille JD, for the LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual. Arthritis Rheum 2006;55:799-806.
2. Budman DR, Steinberg AD. Hematologic aspects of systemic lupus erythematosus: current concepts. Ann Intern Med 1977;86:220-9.
3. Sultan SM, Begum S, Isenberg DA. Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. Rheumatology (Oxford) 2003;42:230-4.
4. Jacobsen S, Petersen J, Ullman S, Junker P, Voss A, Rasmussen JM, et al. A multicentre study of 513 Danish patients with systemic lupus erythematosus. I. Disease manifestations and analyses of clinical subsets. Clin Rheumatol 1998;17:468-77.
5. Mok CC, Lee KW, Ho CT, Lau CS, Wong RW. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford) 2000;39:399-406.
6. Nossent JC, Swaak AJ. Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus. Q J Med 1991;80:605-12.
7. Garcia MA, Marcos JC, Marcos AI, Pons-Estel BA, Wojdyla D, Arturi A, et al. Male systemic lupus erythematosus in a Latin-American inception cohort of 1214 patients. Lupus 2005;14:938-46.
8. Lavalle C, Hurtado R, Quezada JJ, Cabral A, Fraga A. Hemocytopenia as initial manifestation of systemic lupus erythematosus: prognostic significance. Clin Rheumatol 1983;2:227-32.
9. Rottem M, Krause I, Fraser A, Stojanovich L, Rovensky J, Shoenfeld Y. Autoimmune hemolytic anaemia in the antiphospholipid syndrome. Lupus 2006;15:473-7.
10. Kokori SI, Ioannidis JP, Voulgarelis M, Tzioufas AG, Moutsopoulos HM. Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. Am J Med 2000;108:198-204.
11. Davies KA, Robson MG, Peters AM, Norsworthy P, Nash JT, Walport MJ. Defective Fc-dependent processing of immune complexes in patients with systemic lupus erythematosus. Arthritis Rheum 2002;46:1028-38.
12. Edberg JC, Langefeld CD, Wu J, Moser KL, Kaufman KM, Kelly J, et al. Genetic linkage and association of Fcγ receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus. Arthritis Rheum 2002;46:2132-40.
13. Xue C, Lan-Lan W, Bei C, Jie C, Wei-Hua F. Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus [published erratum appears in Cell Immunol 2006;243:127]. Cell Immunol 2006;239:121-8.
14. Chen JY, Wang CM, Ma CC, Chow YH, Luo SF. The -844C/T polymorphism in the Fas ligand promoter associates with Taiwanese SLE. Genes Immun 2005;6:123-8.
15. Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 2006;85:147-56.
16. Alarcon GS, Friedman AW, Straaton KV, Moulds JM, Lisse J, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups: III a comparison of characteristics early in the natural history of the LUMINA cohort. Lupus 1999;8:197-209.
17. Hochberg MC, for Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
18. Reveille JD, Moulds JM, Ahn C, Friedman AW, Baethge B, Roseman J, et al, for the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. Arthritis Rheum 1998;41:1161-72.
19. US Department of Commerce, Bureau of the Census. Current population reports, series P-23, no. 28 and series P-60, no. 68 and subsequent years. Washington (DC): Housing and Household Economic Statistics Division; 1995.
20. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
21. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000;27:373-6.
22. Aarden LA, de Groot ER, Feltkamp TE. Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann N Y Acad Sci 1975;254:505-15.
23. Hamilton RG, Harley JB, Bias WB, Roebber M, Reichlin M, Hochberg MC, et al. Two Ro (SS-A) autoantibody responses in systemic lupus erythematosus: correlation of HLA-DR/DQ specificities with quantitative expression of Ro (SS-A) autoantibody. Arthritis Rheum 1988;31:496-505.
24. Harris EN. Special report: the Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol 1990;94:476-84.
25. Triplett DA, Barna LK, Unger GA. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemost 1993;70:787-93.
26. Alarcon GS, McGwin G Jr, Petri M, Reveille JD, Ramsey-Goldman R, Kimberly RP, et al, for the PROFILE Study Group. Baseline characteristics of a multiethnic lupus cohort: PROFILE [published erratum appears in Lupus 2002;11:402]. Lupus 2002;11:95-101.
27. Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, et al. A novel polymorphic CAAT/enhancer-binding protein β element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 2003;170:132-8.
28. Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user's manual. Boston: The Health Institute, New England Medical Center; 1994.
29. Cohen S, Mermelstein R, Kamarck T, Hoberman HN. Measuring the functional components of social support. In: Sarason IG, Sarason BR, editors. Social support: theory, research and applications. Boston: Martinus Nijhoff; 1985. p. 73-94.
30. Nicassio PM, Wallston KA, Callahan LF, Herbert M, Pincus T. The measurement of helplessness in rheumatoid arthritis: the development of the arthritis helplessness index. J Rheumatol 1985;12:462-7.
31. Engle EW, Callahan LF, Pincus T, Hochberg MC. Learned helplessness in systemic lupus erythematosus: analysis using the Rheumatology Attitude Index. Arthritis Rheum 1990;33:281-6.
32. Pilowsky I. Dimensions of illness behaviour as measured by the Illness Behaviour Questionnaire: a replication study. J Psychosom Res 1993;37:53-62.
33. Alarcon GS, McGwin G Jr, Bartolucci AA, Roseman J, Lisse J, Fessler BJ, et al, for the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum 2001;44:2797-806.
34. Alarcon GS, McGwin G Jr, Bastian HM, Roseman J, Lisse J, Fessler BJ, et al, for the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. VII. Predictors of early mortality in the LUMINA cohort. Arthritis Rheum 2001;45:191-202.
35. Harris EN, Asherson RA, Gharavi AE, Morgan SH, Derue G, Hughes GR. Thrombocytopenia in SLE and related autoimmune disorders: association with anticardiolipin antibody. Br J Haematol 1985;59:227-30.
36. Miller MH, Urowitz MB, Gladman DD. The significance of thrombocytopenia in systemic lupus erythematosus. Arthritis Rheum 1983;26:1181-6.
37. Ziakas PD, Giannouli S, Zintzaras E, Tzioufas AG, Voulgarelis M. Lupus thrombocytopenia: clinical implications and prognostic significance. Ann Rheum Dis 2005;64:1366-9.
38. Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, et al, for the Grupo Latinoamericano de Estudio del Lupus. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanics." Medicine (Baltimore) 2004;83:1-17.
39. Gomard-Mennesson E, Ruivard M, Koenig M, Woods A, Magy N, Ninet J, et al. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus 2006;15:223-31.
40. To CH, Petri M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum 2005;52:4003-10.
41. Hoffman IE, Peene I, Meheus L, Huizinga TW, Cebecauer L, Isenberg D, et al. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis 2004;63:1155-8.
42. Deleze M, Alarcon-Segovia D, Oria CV, Sanchez-Guerrero J, Fernandez-Dominguez L, Gomez-Pacheco L, et al. Hemocytopenia in systemic lupus erythematosus: relationship to antiphospholipid antibodies [published erratum appears in J Rheumatol 1989;16:1523]. J Rheumatol 1989;16:926-30.
43. Sebastiani GD, Galeazzi M, Tincani A, Piette JC, Font J, Allegri F, et al. Anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus: prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE. Scand J Rheumatol 1999;28:344-51.
44. Alarcon GS, Calvo-Alen J, McGwin G Jr, Uribe AG, Toloza SM, Roseman JM, et al, for the LUMINA Study Group. Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. Ann Rheum Dis 2006;65:1168-74.
45. Cooper GS, Parks CG, Treadwell EL, St Clair EW, Gilkeson GS, Cohen PL, et al. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus 2002;11:161-7.